After lengthy discussions, on Tuesday, drugmaker AbbVie announced that it is acquiring Allergan–the maker of the anti-aging treatment we women all do, but don’t talk about–for $63 billion. It’s one of the biggest mergers in the healthcare sector this year. The healthcare experts we spoke to say it’s a win-win for both parties: it will deliver a new source of growth for AbbVie (It’s been too heavily reliant on revenue from Humira, the arthritis drug it produces), and will provide a second wind for Allergan, which has struggled with all sorts of issues – from drug trial setbacks, disappointments with capital deployment, to strategic missteps.

  •  Get NoPo Delivered Daily

    We hate SPAM as much as you do! Rest assured, your information stays private as per our privacy policy.